市場調査レポート

子宮頸がん治療薬市場とパイプライン分析

Cervical Cancer Drug Market & Pipeline Insight

発行 PNS Pharma 商品コード 317352
出版日 ページ情報 英文 165 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
子宮頸がん治療薬市場とパイプライン分析 Cervical Cancer Drug Market & Pipeline Insight
出版日: 2014年06月01日 ページ情報: 英文 165 Pages
概要

子宮頸がんは世界中の女性にとって、3番目に発生件数が多く、4番目に死亡件数が多いがんです。早期発見により、この数年は子宮頸がんによる死亡率は減少傾向にありますが、過剰診断および過剰処置などの課題が依然として残されています。世界保健機関(WHO)によると、毎年新たに50万人以上が子宮頸がんと診断され、毎年27万5,000人近くが命を落としています。このため、依然として子宮頸がんは他のがんの中でも重大な健康問題とと位置付けられています。

当レポートでは、子宮頸がん治療薬市場について調査し、市場概要、フェーズ・国別の臨床分析、上市薬、未開発および臨床試験が中止された治療薬のプロファイルおよび競合情勢をまとめるなど、概略以下の構成でお届けいたします。

第1章 子宮頸がん治療薬市場の概要

  • 市場概要
  • 臨床パイプライン分析

第2章 子宮頸がん臨床試験分析、フェーズ別・国別

  • 前臨床
  • 臨床
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズIII

第3章 上市済み子宮頸がん治療薬臨床分析および特許分析

第4章 中止および未開発の子宮頸がん治療薬

  • 未開発
  • 中止

第5章 競合情勢

  • Advaxis
  • ApoVax
  • Genentech
  • GlaxoSmithKline
  • Inovio Pharmaceuticals
  • ISA Pharmaceuticals
  • 科研製薬
  • Merck

図表リスト

目次

Cervical cancer is the third and fourth most common cause of cancer incidence and mortality among women across the world. Though there has been a decline in cervical cancer mortality rates in the previous few years, owing to early detection and intervention, challenges like over-diagnosis and over-treatment of the disease continue to remain. As per the World Health Organization (WHO), more than half a million new cases are diagnosed annually and there are close to 275,000 deaths every year. Thus, cervical cancer continues to be a major public health problem among the other cancers.

Significant amount of research is being undertaken to study the process of HPV infection causing precancerous changes in normal cells, which eventually leads to cervical cancer. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Once the results of these research activities are proved, there would be a major shift in the methods of treating this disease in the future.

Since there are no therapeutic vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. The current therapeutic vaccines have shown some systematic cellular immunity by intramuscular or subcutaneous injection. This has led the clinical trials to show cellular immune response to the vaccines. However, mucosal immunity at cervical mucosa is required and the pharma companies are currently focusing on this aspect. With the development of vaccines addressing this issue, there would be a significant reduction in the incidence rates of HPV across the globe.

Efforts are being made by the stakeholders to invest larger quantities of time and resources in obtaining a greater and deeper understanding of laboratory research which has indicated that HPVs (which are the major cause of cervical cancer), produce proteins which are called E5, E6, and E7. These proteins tend to interfere with the functions of the cells which normally prevent excessive growth. With a better knowledge of the mechanisms and working of these proteins, researchers could possibly be able to develop successful ways to limit the process by which HPV infection can lead to the growth of abnormal cells, thus controlling the incidence of cervical cancer.

"Cervical Cancer Drug Market & Pipeline Insight" Report Highlights:

  • Cervical Cancer Drug Market Overview
  • Marketed Drug Profiles & Patent Analysis
  • Clinical Trial Insight by Phase & Country
  • Drug in Clinical Development Phase: 47
  • Majority Drugs in Phase-II: 16
  • Marketed Cervical Cancer Drug: 6
  • Discontinued Drug Profiles: 26
  • Competitive Landscape

Table of Contents

1. Cervical Cancer Drug Market Overview

  • 1.1 Market Overview
  • 1.2 Clinical Pipeline Insight

2. Cervical Cancer Drug Clinical Trial Insight by Phase & Country

  • 2.1 Preclinical
  • 2.2 Clinical
  • 2.3 Phase I
  • 2.4 Phase I/II
  • 2.5 Phase II
  • 2.6 Phase III

3. Marketed Cervical Cancer Drug Clinical Insight & Patent Analysis

4. Discontinued & No Development Reported in Cervical Cancer Drug

  • 4.1 No Development Reported
  • 4.2 Discontinued

5. Competitive Landscape

  • 5.1 Advaxis
  • 5.2 ApoVax
  • 5.3 Genentech
  • 5.4 GlaxoSmithKline
  • 5.5 Inovio Pharmaceuticals
  • 5.6 ISA Pharmaceuticals
  • 5.7 Kaken Pharmaceutical
  • 5.8 Merck
  • Figure 1- 1: US - Number Cervical Cancer New Cases & Deaths, 2014
  • Figure 1- 2: Global Cervical Cancer Market (US$), 2013-2020
  • Figure 1- 3: Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Figure 1- 4: Number of Cervical Cancer Drugs in Pipeline by Phase, 2014
  • Figure 1- 5: No Development in Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Figure 1- 6: No Development in Cervical Cancer Drugs in Pipeline by Phase (Number), 2014
  • Figure 1- 7: Discontinued Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Figure 1- 8: Number of Discontinued Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Table 1-1: Europe - Cervical Cancer Estimated Incidence & Mortality by country, 2012

Following Information for Each Drug Profile is Covered in More than 200 Tables in Report:

  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class

List of Figures & Tables

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top